Full-Time

Senior Manager

Companion Diagnostics

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$158k - $198kAnnually

Senior

San Carlos, CA, USA

This is a hybrid position, requiring some in-office days.

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Lead the development and implementation of diagnostic strategies for individual studies and/or molecule program.
  • Direct the development, outsourcing and validation of clinically applicable in vitro diagnostic assays through the development lifecycle of molecules, including design, implement and oversee diagnostic testing strategy and timely communication with key internal and external stakeholders.
  • Provide expertise to development project teams to ensure access to state-of-the-art approaches on appropriate diagnostic technologies, evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to the proposed companion diagnostic assay.
  • Oversee implementation of clinical trial assays at CRO laboratories for centralized testing. Monitors of all scope or changes in study are timely implemented, including the development of the work order, costs and agreements.
  • Individuals may lead joint development teams between RevMed and Dx partners to ensure alignment of overarching development and commercialization strategy, successful fit for purpose CDx development and that co-development timelines are met.
  • Serve as subject matter expert in state-of-the-art biomarker testing technologies (tissue and ctDNA NGS, PCR, immunohistochemistry, FISH, , etc.)
  • Serve as subject matter expert and support the interactions with global health authorities regarding companion diagnostics development and submissions.
Desired Qualifications
  • Highly experienced biomarker or diagnostics professional (MS and/or PhD) with a minimum of 5-7 years of relevant industry experience with expertise in oncology biomarker and/or companion diagnostic development
  • High level of initiative and ability to work independently with business awareness, hands on experience in IVD development processes and global in vitro diagnostic regulatory aspects related to companion diagnostic development
  • Experience with biomarker application in clinical trials and awareness of the challenges of implementing diagnostic technologies in the clinical setting
  • Excellent leadership skills including motivation and influencing without authority.
  • Highly collaborative team player who fosters open communication and facilitates mutual understanding and cooperation between all stakeholders with excellent communication, analytical and organizational skills.
  • Cross-functional experience in commercial and or medical aspects of companion diagnostics is a plus.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.

NS Healthcare
Aug 2nd, 2023
Revolution Medicines agrees to buy EQRx in all-stock transaction

Revolution Medicines, engaged in the development of targeted therapies for RAS-addicted cancers, has forged an agreement to acquire NS Healthcare drugmaker EQRx in an all-stock transaction.

Pharmatching
Aug 2nd, 2023
Revolution Medicines agrees to buy US drugmaker EQRx

Revolution Medicines agrees to buy Pharmatching GmbH drugmaker EQRx.

Market Wire News
Aug 1st, 2023
EQRX - Revolution Medicines inc. to acquire EQRx inc. in all-stock Transaction to gain more than $1 billion in additional capital

Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (“EQRx”) (Nasdaq: EQRX) today announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet.

Google News
Jun 23rd, 2023
CFO Jack Anders Sells 1,249 Sh

Additionally, Revolution Medicines is developing a series of inhibitors targeting multiple mutant RAS proteins and SOS1, as well as inhibitors of other key oncogenic drivers.

GlobeNewswire
Mar 3rd, 2023
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...